The FDA reversed its decision regarding a gene therapy application from uniQure N.V.
2 reports, 2 independent
Updated 00:00
Still developing
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA reversed its decision regarding a gene therapy application from uniQure N.V.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA made a decision on uniQure N.V.'s gene therapy application.1 source
FDA reversed course on a gene therapy application from uniQure N.V.1 source
Keep exploring
The entities involved
Related events
- The FDA requested additional clinical data from Unicycive Therapeutics.
- FDA removed the clinical hold on Arbutus Biopharma Corporation's IND application, allowing potential clinical development.
- Litigation regarding FDA approval process.
- Cardiff Oncology and Nerviano Medical Sciences are seeking FDA regulatory review for Phase 3 trials and managing a licensing dispute over onvansertib.